Alternatives routes of insulin delivery.
暂无分享,去创建一个
[1] M. Foldvari,et al. Evidence for lymphatic transport of insulin by topically applied biphasic vesicles , 2003, The Journal of pharmacy and pharmacology.
[2] Y. Miyazaki,et al. Dose-response effect of a single administration of oral hexyl-insulin monoconjugate 2 in healthy nondiabetic subjects. , 2004, Diabetes care.
[3] B. Aungst. Site-dependence and structure-effect relationships for alkylglycosides as transmucosal absorption promoters for insulin , 1994 .
[4] Nick Freemantle,et al. Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes. , 2005, Diabetes care.
[5] J. Manson,et al. Intranasal aerosolized insulin. Mixed-meal studies and long-term use in type I diabetes. , 1985 .
[6] L. Machet,et al. Phonophoresis: efficiency, mechanisms and skin tolerance. , 2002, International journal of pharmaceutics.
[7] M. Singh,et al. Structure-activity relationship of chemical penetration enhancers in transdermal drug delivery. , 2000, Current medicinal chemistry.
[8] Jim Wright,et al. Dose delivery characteristics of the AIR pulmonary delivery system over a range of inspiratory flow rates. , 2005, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.
[9] M. Kisel,et al. Liposomes with phosphatidylethanol as a carrier for oral delivery of insulin: studies in the rat. , 2001, International journal of pharmaceutics.
[10] R. Greenwood,et al. Buccal administration of human insulin in streptozocin-diabetic rats. , 1993, Research communications in chemical pathology and pharmacology.
[11] I. Kwon,et al. Self-assembled “nanocubicle” as a carrier for peroral insulin delivery , 2002, Diabetologia.
[12] J. Hadgraft,et al. Modulation of the Barrier Function of the Skin , 2001, Skin Pharmacology and Physiology.
[13] P. Maincent,et al. Formulation of Insulin-Loaded Polymeric Nanoparticles Using Response Surface Methodology , 2005, Drug development and industrial pharmacy.
[14] B. Aungst,et al. Site Dependence of Absorption-Promoting Actions of Laureth-9, Na Salicylate, Na2EDTA, and Aprotinin on Rectal, Nasal, and Buccal Insulin Delivery , 1988, Pharmaceutical Research.
[15] S. Mudaliar,et al. Dose-response relationships of inhaled insulin delivered via the Aerodose insulin inhaler and subcutaneously injected insulin in patients with type 2 diabetes. , 2003, Diabetes care.
[16] G. Cevc. Transdermal Drug Delivery of Insulin with Ultradeformable Carriers , 2003, Clinical pharmacokinetics.
[17] L. Heinemann,et al. Inhaled micronized crystalline human insulin using a dry powder inhaler: dose‐response and time‐action profiles 1 , 2004, Diabetic medicine : a journal of the British Diabetic Association.
[18] S. Davis,et al. Intranasal Insulin , 1992, Clinical pharmacokinetics.
[19] J. Pickup. Biotechnology of insulin therapy , 1991 .
[20] F. Patat,et al. Effect of sonication parameters on transdermal delivery of insulin to hairless rats. , 2002, Journal of controlled release : official journal of the Controlled Release Society.
[21] Michael Yianneskis,et al. Drug delivery to the respiratory tract using dry powder inhalers , 1994 .
[22] S. Fineberg,et al. Antibody response to inhaled insulin in patients with type 1 or type 2 diabetes. An analysis of initial phase II and III inhaled insulin (Exubera) trials and a two-year extension trial. , 2005, The Journal of clinical endocrinology and metabolism.
[23] S. Mudaliar,et al. Young and Elderly Type 2 Diabetic Patients Inhaling Insulin with the AERx® Insulin Diabetes Management System: A Pharmacokinetic and Pharmacodynamic Comparison , 2003, Journal of clinical pharmacology.
[24] Qiang Zhang,et al. Sublingual delivery of insulin: effects of enhancers on the mucosal lipid fluidity and protein conformation, transport, and in vivo hypoglycemic activity. , 2005, Biological & pharmaceutical bulletin.
[25] A. Barnett,et al. Inhaled insulin: new technology, new possibilities , 2006, International journal of clinical practice.
[26] R. Becker,et al. The effect of smoking cessation and subsequent resumption on absorption of inhaled insulin. , 2006, Diabetes care.
[27] S. Fineberg. Diabetes therapy trials with inhaled insulin , 2006, Expert opinion on investigational drugs.
[28] W. Cefalu,et al. Inhaled Human Insulin Treatment in Patients with Type 2 Diabetes Mellitus , 2001, Annals of Internal Medicine.
[29] Donald E. Chickering,et al. Biologically erodable microspheres as potential oral drug delivery systems , 1997, Nature.
[30] B. W. Barry,et al. Novel mechanisms and devices to enable successful transdermal drug delivery. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[31] M. Aprahamian,et al. Ileal Uptake of Polyalkylcyanoacrylate Nanocapsules in the Rat , 2000, The Journal of pharmacy and pharmacology.
[32] J. Varshosaz,et al. Nasal Delivery of Insulin Using Bioadhesive Chitosan Gels , 2006, Drug delivery.
[33] W. Ritschel,et al. Absorption characteristics of insulin through the buccal mucosa. , 1990, Methods and Findings in Experimental and Clinical Pharmacology.
[34] V. Lassmann-Vague. [Unusual ways of insulin administration]. , 1988, Diabete & metabolisme.
[35] A. Pfützner,et al. Technosphere/Insulin--a new approach for effective delivery of human insulin via the pulmonary route. , 2002, Diabetes technology & therapeutics.
[36] T. Heise,et al. Intrasubject variability of inhaled insulin in type 1 diabetes: a comparison with subcutaneous insulin. , 2004, Diabetes technology & therapeutics.
[37] S. Madsbad,et al. Intranasal insulin therapy: the clinical realities , 1995, Diabetologia.
[38] I. Raz,et al. Dose-response relationship of oral insulin spray in healthy subjects. , 2005, Diabetes care.
[39] I. Raz,et al. Dose-response relationship of an oral insulin spray in six patients with type 1 diabetes: a single-center, randomized, single-blind, 5-way crossover study. , 2005, Clinical therapeutics.
[40] G. Slama,et al. Efficacy and tolerance of intranasal insulin administered during 4 months in severely hyperglycaemic Type 2 diabetic patients with oral drug failure: a cross‐over study , 2001, Diabetic medicine : a journal of the British Diabetic Association.
[41] J. Guevara-Aguirre,et al. Oral spray insulin in treatment of type 2 diabetes: a comparison of efficacy of the oral spray insulin (Oralin) with subcutaneous (SC) insulin injection, a proof of concept study , 2004, Diabetes/metabolism research and reviews.
[42] R. Langer,et al. Drug delivery and targeting. , 1998, Nature.
[43] W. Cefalu,et al. Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study , 2001, The Lancet.
[44] C. Dunn,et al. Inhaled human insulin (Exubera): a review of its use in adult patients with diabetes mellitus. , 2006, Drugs.
[45] R. DeFronzo,et al. Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise: a 12-week, randomized, comparative trial. , 2005, Diabetes care.
[46] Lawrence Blonde,et al. Efficacy and safety of inhaled insulin (exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial. , 2004, Diabetes care.
[47] Y. Kalia,et al. Non‐invasive assessment of the effects of iontophoresis on human skin in‐vivo , 2001, The Journal of pharmacy and pharmacology.
[48] J. Rosenstock,et al. Efficacy and safety of preprandial human insulin inhalation powder versus injectable insulin in patients with type 1 diabetes , 2006, Diabetologia.
[49] J. Still. Development of oral insulin: progress and current status. , 2002 .
[50] J. Patton,et al. Mechanisms of macromolecule absorption by the lungs , 1996 .
[51] Joseph C Cappelleri,et al. Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera) in patients with type 1 or type 2 diabetes. , 2004, Diabetes care.
[52] L. Heinemann,et al. Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. , 2005, Diabetes care.
[53] M. Ellmerer,et al. Dose-response relation of liquid aerosol inhaled insulin in Type I diabetic patients , 2001, Diabetologia.
[54] J. Brand,et al. LACTOSE INTOLERANCE AND YOGHURT , 1980, The Lancet.
[55] S. Mitragotri,et al. Low-frequency sonophoresis: a review. , 2004, Advanced drug delivery reviews.
[56] P. Raskin,et al. Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: a 6-month, randomized, comparative trial. , 2005, Diabetes care.
[57] B. Buckley,et al. Pharmacokinetics and pharmacodynamics of intranasal insulin administered to patients with type 1 diabetes: a preliminary study. , 2006, Diabetes technology & therapeutics.
[58] Bernard Lennox,et al. NORMALISATION: A POSSIBLE GENERAL SOLUTION TO THE UNITS PROBLEM , 1975, The Lancet.
[59] P. Byron. Prediction of drug residence times in regions of the human respiratory tract following aerosol inhalation. , 1986, Journal of pharmaceutical sciences.
[60] T. Quattrin,et al. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial. , 2004, Diabetes care.
[61] B. Zinman,et al. Alternative routes of insulin delivery , 2003, Diabetic medicine : a journal of the British Diabetic Association.
[62] A. McElduff,et al. Pulmonary insulin administration using the AERx system: physiological and physicochemical factors influencing insulin effectiveness in healthy fasting subjects. , 2000, Diabetes technology & therapeutics.
[63] T. Rönnemaa,et al. Intensive therapy with inhaled insulin via the AERx insulin diabetes management system: a 12-week proof-of-concept trial in patients with type 2 diabetes. , 2004, Diabetes care.
[64] P. Kam,et al. Influence of acute upper respiratory tract infection on the absorption of inhaled insulin using the AERx insulin Diabetes Management System. , 2005, British journal of clinical pharmacology.
[65] N. Freemantle,et al. Will availability of inhaled human insulin (Exubera®) improve management of type 2 diabetes? The design of the Real World trial , 2006, Trials.
[66] Biana Godin,et al. Ethosomes: new prospects in transdermal delivery. , 2003, Critical reviews in therapeutic drug carrier systems.
[67] A. Turner-Henson,et al. Insulin administration to the eyes of normoglycemic human volunteers. , 1994, Journal of ocular pharmacology.
[68] R. V. Morgan,et al. Delivery of systemic regular insulin via the ocular route in dogs. , 1996, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.
[69] R. Reinhardt,et al. Effects of different durations of breath holding after inhalation of insulin using the AERx insulin diabetes management system. , 2003, Clinical therapeutics.
[70] J. Hankiss. Insulin given intranasally induces hypoglycaemia in normal and diabetic subjects. , 1982, British medical journal.
[71] G. Slama,et al. Six month administration of gelified intranasal insulin in 16 type 1 diabetic patients under multiple injections: efficacy vs subcutaneous injections and local tolerance. , 2001, Diabetes & metabolism.
[72] G. Jerums,et al. Long-Term Use of Intranasal Insulin in Insulin-Dependent Diabetic Patients , 1987, Diabetes Care.
[73] Carino,et al. Oral insulin delivery. , 1999, Advanced drug delivery reviews.
[74] Jeff Schuster,et al. The AERX™ Aerosol Delivery System , 1997, Pharmaceutical Research.
[75] G. Schellenberg,et al. Effects of intranasal insulin on cognition in memory-impaired older adults: Modulation by APOE genotype , 2006, Neurobiology of Aging.
[76] Y. Kalia,et al. Factors and strategies for improving buccal absorption of peptides. , 2001, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[77] A. Fernandez-cruz,et al. Changes in the density and localisation of endothelin receptors in the early stages of rat diabetic retinopathy and the effect of insulin treatment , 2000, Diabetologia.
[78] M. Kipnes,et al. Control of postprandial plasma glucose by an oral insulin product (HIM2) in patients with type 2 diabetes. , 2003, Diabetes care.
[79] Adrian C. Williams,et al. Can drug‐bearing liposomes penetrate intact skin? , 2006, The Journal of pharmacy and pharmacology.
[80] S. Yalkowsky,et al. Systemic absorption of insulin from a Gelfoam ocular device. , 1999, International journal of pharmaceutics.
[81] J. Born,et al. Intranasal Insulin Improves Memory in Humans: Superiority of Insulin Aspart , 2007, Neuropsychopharmacology.
[82] M. Mihic,et al. The evolving role of oral insulin in the treatment of diabetes using a novel RapidMist™ System , 2002, Diabetes/metabolism research and reviews.
[83] S. Mitragotri,et al. Current status and future potential of transdermal drug delivery , 2004, Nature Reviews Drug Discovery.
[84] S. Clement,et al. Oral modified insulin (HIM2) in patients with type 1 diabetes mellitus: results from a phase I/II clinical trial. , 2004, Metabolism: clinical and experimental.
[85] G. Slama,et al. PREPRANDIAL INTRANASAL INSULIN AS ADJUVANT THERAPY IN TYPE II DIABETICS , 1987, The Lancet.
[86] L. Heinemann,et al. Absorption and metabolic effect of inhaled insulin: intrapatient variability after inhalation via the Aerodose insulin inhaler in patients with type 2 diabetes. , 2002, Diabetes care.
[87] J. Bluestone,et al. Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. , 2006, The Journal of clinical investigation.
[88] Selcan Türker,et al. Nasal route and drug delivery systems , 2004, Pharmacy World and Science.
[89] P. Wertz,et al. Drug delivery via the buccal mucosa , 1998 .
[90] Y. Chien,et al. Systemic delivery of peptides and proteins across absorptive mucosae. , 1996, Critical reviews in therapeutic drug carrier systems.
[91] A. Himmelmann,et al. The impact of smoking on inhaled insulin. , 2003, Diabetes care.
[92] G. Cevc. Transfersomes, liposomes and other lipid suspensions on the skin: permeation enhancement, vesicle penetration, and transdermal drug delivery. , 1996, Critical reviews in therapeutic drug carrier systems.
[93] T. Heise,et al. The effect of insulin antibodies on the metabolic action of inhaled and subcutaneous insulin: a prospective randomized pharmacodynamic study. , 2005, Diabetes care.
[94] S. Jain,et al. Transfersomes—A Novel Vesicular Carrier for Enhanced Transdermal Delivery: Development, Characterization, and Performance Evaluation , 2003, Drug development and industrial pharmacy.
[95] L. Heinemann,et al. Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro. , 2005, Diabetes care.
[96] T. Stanley,et al. An in vivo dog model for studying recovery kinetics of the buccal mucosa permeation barrier after exposure to permeation enhancers: apparent evidence of effective enhancement without tissue damage , 1994 .
[97] V. Lassmann-Vague,et al. PREPRANDIAL INTRANASAL INSULIN , 1988, The Lancet.
[98] B. Zinman,et al. Inhaled Insulin Improves Glycemic Control When Substituted for or Added to Oral Combination Therapy in Type 2 Diabetes , 2005, Annals of Internal Medicine.
[99] F. Plakogiannis,et al. Oral absorption of insulin encapsulated in artificial chyles of bile salts, palmitic acid and alpha-tocopherol dispersions. , 2002, International journal of pharmaceutics.
[100] H. Schulz. Mechanisms and factors affecting intrapulmonary particle deposition: implications for efficient inhalation therapies Holger Schulz , 1998 .
[101] S. Mudaliar,et al. Inhaled insulin using the AERx Insulin Diabetes Management System in healthy and asthmatic subjects. , 2003, Diabetes care.
[102] P. Pozzilli,et al. Biokinetics of buccal spray insulin in patients with type 1 diabetes. , 2005, Metabolism: clinical and experimental.
[103] G. Chiou,et al. Alternative delivery of insulin via eye drops. , 2005, Diabetes technology & therapeutics.
[104] R. Guy,et al. Iontophoresis of monomeric insulin analogues in vitro: effects of insulin charge and skin pretreatment. , 1998, Journal of controlled release : official journal of the Controlled Release Society.